



PRESS RELEASE
06 February 2026 11:00:00 CET

Invitation to the Presentation of Cantargia's Annual Results for 2025

Cantargia AB (publ) (Nasdaq Stockholm: CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CET.

In conjunction to the report, investors, analysts, and media are invited to an audiocast with teleconference (in English) on February 20, at 3:00 p.m. CET, where Cantargia's CEO Hilde Steineger, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.

If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: <https://cantargia.events.inderes.com/q4-report-2025>.

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://events.inderes.com/cantargia/q4-report-2025/dial-in>.

The webcast will also be available on demand on Cantargia's corporate website: www.cantargia.com

For further information, please contact

Hilde Steineger, CEO
Telephone: +46 (0)46-275 62 60
E-mail: info@cantargia.com

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer and non-small cell lung cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.



PRESS RELEASE
06 February 2026 11:00:00 CET

Attachments

Invitation to the Presentation of Cantargia's Annual Results for 2025